(Q47808621)

5 February 2018

title

Alemtuzumab induced complete remission of romidepsin-refractory large cell transformation of mycosis fungoides (English)

1 reference

5 February 2018

author name string

Yok-Lam Kwong

series ordinal

1

1 reference

5 February 2018

publication date

11 August 2013

1 reference

5 February 2018

published in

Annals of Hematology

1 reference

5 February 2018

volume

93

1 reference

5 February 2018

issue

4

1 reference

5 February 2018

page(s)

713-714

1 reference

5 February 2018

Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1869-Z

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1869-Z

Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1869-Z

Non-bacterial infections in Asian patients treated with alemtuzumab: a retrospective study of the Asian Lymphoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1869-Z

Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1869-Z

10.1007/S00277-013-1869-Z

21 January 2018

Identifiers

DOI

1 reference

5 February 2018

1 reference

5 February 2018